Labrida BioClean
Commercial- Indications
- Peri-implantitis, Periodontitis
Company intelligence / Profile preview
Labrida’s lead product, the chitosan-based BioClean® brush, has demonstrated significant reduction in pocket depth and inflammation around dental implants and teeth in clinical studies. It offers a gentle, biocompatible alternative for debridement with increased patient comfort compared to traditional methods. The device reduces aerosol generation during procedures—a benefit highlighted during the COVID era—and supports both surgical and non-surgical maintenance of oral health. The company has entered a major distribution partnership with Straumann Group to expand global reach.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Labrida.